It's been a long legal road for Copaxone, and one that took yet another turn Thursday as the U.S. Court of Appeals struck down the drug's patent for the second time.

In January, the U.S. Supreme Court ruled in maker Teva's ($TEVA) favor, reversing an initial appeals-court ruling that had invalidated Copaxone's IP shield and sending the case back down for reconsideration. But now, after taking another look, the court has come back to the same conclusion it initially reached almost two years ago, The Wall S